0001209191-23-002190.txt : 20230105 0001209191-23-002190.hdr.sgml : 20230105 20230105211236 ACCESSION NUMBER: 0001209191-23-002190 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230103 FILED AS OF DATE: 20230105 DATE AS OF CHANGE: 20230105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kalowski Lee CENTRAL INDEX KEY: 0001618273 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38916 FILM NUMBER: 23513515 MAIL ADDRESS: STREET 1: C/O TOKAI PHARMACEUTICALS, INC. STREET 2: ONE BROADWAY, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc CENTRAL INDEX KEY: 0001761612 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: BLOCKS A & B, PORTWAY BUILDING STREET 2: GRANTA PARK, GREAT ABINGTON CITY: CAMBRIDGE STATE: X0 ZIP: CB21 6GS BUSINESS PHONE: 011441223261503 MAIL ADDRESS: STREET 1: BLOCKS A & B, PORTWAY BUILDING STREET 2: GRANTA PARK, GREAT ABINGTON CITY: CAMBRIDGE STATE: X0 ZIP: CB21 6GS FORMER COMPANY: FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd DATE OF NAME CHANGE: 20181212 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-03 0 0001761612 BICYCLE THERAPEUTICS plc BCYC 0001618273 Kalowski Lee C/O BICYCLE THERAPEUTICS PLC BLOCKS A & B, PORTWAY BUILDING CAMBRIDGE X0 CB21 6GS UNITED KINGDOM 0 1 0 0 President and CFO Ordinary Shares 2023-01-03 4 A 0 17500 0.00 A 32500 D Ordinary Shares 2023-01-03 4 S 0 1815 29.06 D 30685 D Employee Stock Option (right to buy) 29.60 2023-01-03 4 A 0 35000 0.00 A 2033-01-03 Ordinary Shares 35000 35000 D Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 3, 2024 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. Each RSU represents a contingent right to receive one ordinary share. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.545 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 3, 2024 and the remaining shares in 36 equal monthly installments thereafter. /s/ Lee Kalowski 2023-01-05